































staff,	 hospital	 beds	 and	 equipment	 to	 handle	 the	 massive	 influx	 of	 patients.	 Surgical	 procedures	
were	 cancelled	 for	 all	 but	 the	most	 urgent	 cases.[2]	 In	 this	 issue	 of	BMJ	 Quality	 and	 Safety,	 the	
Corona	Hand	Collaborative	group	 report	 the	 results	of	a	cohort	 study	conducted	over	a	 two-week	
period	in	April	2020,	during	the	peak	of	the	first	wave	of	the	COVID-19	pandemic	in	the	UK.[3]	Data	
were	 collected	 for	 1093	 patients	 undergoing	 upper-limb	 surgery	 in	 74	 NHS	 hospitals.	 A	 clinician	
survey	captured	data	describing	surgical	cancellations,	operating	room	capacity	and	infection	control	












testing	early	 in	 the	pandemic,	 the	authors’	definition	of	 SARS-CoV-2	 included	patients	with	a	high	













contrasts	 with	 the	 low	 rate	 of	 mortality	 reported	 by	 the	 Corona	 Hand	 Collaborative.	 This	 likely	
relates	to	the	broad	range	of	procedures	included	in	the	COVIDSurg	cohort,	with	higher	baseline	risk	
of	morbidity	compared	to	low-risk	surgical	procedures	such	as	upper	limb	surgery.	Three	quarters	of	
patients	 in	 COVIDSurg	 received	 general	 anaesthesia,	 compared	 to	 one	 third	 in	 the	 Corona	 Hands	
study.	 Some	 commentators	 have	 raised	 concern	 about	 delivering	 general	 anaesthesia	 to	 patients	






To	 facilitate	 the	 COVID-19	 response	 during	 the	 first	 wave,	 the	 majority	 of	 elective	 care	 was	
suspended.	 Consistent	 with	 guidance	 from	 NHS	 England,	 almost	 all	 of	 the	 400,000	 elective	 NHS	
surgical	 procedures	 that	 occur	 every	month	were	 cancelled.[2,7]	 The	 Corona	 Hands	 Collaborative	









Many	 preventative	 measures	 implemented	 in	 wider	 society,	 such	 as	 social	 distancing	 and	 use	 of	
face-coverings,	are	focussed	on	reducing	virus	prevalence	to	protect	susceptible	patient	groups.[10]	
In	 hospitals	 we	 now	 have	 enhanced	 infection	 control	 procedures,	 including	 routine	 preoperative	
SARS-CoV-2	 testing	and	 stringent	 isolation	precautions	 in	hospitals.	 These	measures	have	 reduced	
surgical	 throughput	 substantially,	 even	 before	 we	 consider	 the	 additional	 impact	 from	 re-




continue	 like	 it	 did	 before	 the	 pandemic	 started.	 It	 is	 inevitable	 that	 surgical	waiting	 lists	will	 get	
longer	with	associated	impact	on	outcomes	for	patients	requiring	time-critical	treatments.	There	has	
also	 been	 a	 substantial	 reduction	 in	 secondary	 care	 referrals,	 including	 referrals	 into	 cancer	
pathways.	 [11,12]	This	 suggests	 that	 the	burden	of	untreated	surgical	disease	 in	 the	community	 is	
even	greater	 than	current	waiting	 lists	would	 indicate.	While	 there	have	been	many	direct	deaths	
due	to	COVID-19,	we	expect	a	substantial	number	of	additional	deaths	due	to	delays	 in	 treatment	
amongst	patients	with	other	 life-threatening	diseases.[13]	At	 least	 in	 the	UK,	 there	 is	now	a	 clear	
national	policy	 intent	 to	continue	routine	healthcare	alongside	treatment	 for	patients	with	COVID-
19.	 The	 prevalence	 of	 COVID-19	 dipped	 during	 summer	 months,	 but	 the	 recent	 resurgence	 will	
inevitably	 result	 in	 a	 higher	 in-hospital	 prevalence.	 With	 regional	 fluctuations	 in	 community	
prevalence,	 decisions	 about	 screening,	 isolation	 and	 cancellation	 of	 surgery	 must	 be	 made	
dynamically.	From	the	point	of	view	of	patients	and	their	surgeons,	this	will	mean	regular	changes	in	
infection	control	policies	which	we	know	will	 lead	 to	 frustration.	We	will	never	completely	escape	
the	 tension	between	the	need	to	 resume	surgical	 treatment	of	diseases,	and	 the	risk	 to	 individual	
patients	who	may	experience	worse	outcomes	if	they	contract	COVID-19.	
	
The	 Corona	 Hands	 Collaborative	 are	 to	 be	 congratulated	 for	 completing	 this	 large	 study	 under	
exceptionally	 difficult	 circumstances.	 They	 provide	 reassuring	 data	 for	 young,	 fit	 patients	 who	
require	 low-risk	ambulatory	 surgery.	However,	 the	 skewed	 risk	of	 severe	complications	associated	
with	 COVID-19	 as	 age	 increases	means	 that	 these	 findings	may	 not	 be	 so	 easily	 applied	 to	 older	
patients	 undergoing	major	 surgery,	 especially	 abdominal	 cancer	 surgery.[9]	 The	 risks	 of	 admitting	
patients	 to	 hospital	 without	 rigorous	 infection	 control	 measures	 have	 not	 been	 explored	 in	 this	
study.	Whatever	decisions	are	made,	the	balance	between	harm	from	the	disease	COVID-19	and	the	
harm	 caused	 by	 disruption	 of	 usual	 healthcare	 will	 have	 consequences	 for	 millions	 of	 people.	
Inevitably	 this	 means	 the	 decision	 will	 be	 made	 by	 politicians	 elected	 to	 represent	 the	 views	 of	
society,	with	advice	rather	than	instruction	from	healthcare	experts.	Finally,	one	lingering	question	
remains	–	what	will	 the	outcome	be	 for	 the	millions	of	patients	who	may	never	 get	 their	 surgical	
treatment?	 Given	 the	 inexplicable	 rise	 in	 provision	 of	 surgical	 treatments,	will	 we	 find	 that	 some	
surgeries	are	not	as	necessary	as	we	previously	thought?[7,14]				 	
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